Oncternal Therapeutics, Inc.Oncternal Therapeutics, Inc.Oncternal Therapeutics, Inc.

Oncternal Therapeutics, Inc.

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪2.22 M‬USD
−11.6944USD
‪−39.48 M‬USD
‪785.00 K‬USD
‪2.65 M‬
Beta (1Y)
−0.66
Employees (FY)
27
Change (1Y)
−3 −10.00%
Revenue / Employee (1Y)
‪29.07 K‬USD
Net income / Employee (1Y)
‪−1.46 M‬USD

About Oncternal Therapeutics, Inc.


CEO
James B. Breitmeyer
Headquarters
San Diego
Founded
1997
FIGI
BBG000BX50F2
Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Its product pipeline include Zilovertamab, ONCT-216, ONCT-808 and ONCT-534. The company was founded by David F. Hale and James B. Breitmeyer in September 1997 and is headquartered in San Diego, CA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of ONCT is 0.7474 USD — it has increased by 5.63% in the past 24 hours. Watch Oncternal Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Oncternal Therapeutics, Inc. stocks are traded under the ticker ONCT.
ONCT stock has fallen by −29.91% compared to the previous week, the month change is a −49.32% fall, over the last year Oncternal Therapeutics, Inc. has showed a −90.03% decrease.
We've gathered analysts' opinions on Oncternal Therapeutics, Inc. future price: according to them, ONCT price has a max estimate of 2.00 USD and a min estimate of 2.00 USD. Watch ONCT chart and read a more detailed Oncternal Therapeutics, Inc. stock forecast: see what analysts think of Oncternal Therapeutics, Inc. and suggest that you do with its stocks.
ONCT reached its all-time high on Apr 25, 2007 with the price of 33,096.0000 USD, and its all-time low was 1.0300 USD and was reached on Nov 13, 2024. View more price dynamics on ONCT chart.
See other stocks reaching their highest and lowest prices.
ONCT stock is 9.59% volatile and has beta coefficient of −0.66. Track Oncternal Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Oncternal Therapeutics, Inc. there?
Today Oncternal Therapeutics, Inc. has the market capitalization of ‪2.22 M‬, it has increased by 1.75% over the last week.
Yes, you can track Oncternal Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Oncternal Therapeutics, Inc. is going to release the next earnings report on Mar 6, 2025. Keep track of upcoming events with our Earnings Calendar.
ONCT net income for the last quarter is ‪−8.46 M‬ USD, while the quarter before that showed ‪−8.56 M‬ USD of net income which accounts for 1.11% change. Track more Oncternal Therapeutics, Inc. financial stats to get the full picture.
No, ONCT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 28, 2024, the company has 27.00 employees. See our rating of the largest employees — is Oncternal Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Oncternal Therapeutics, Inc. EBITDA is ‪−35.96 M‬ USD, and current EBITDA margin is ‪−5.31 K‬%. See more stats in Oncternal Therapeutics, Inc. financial statements.
Like other stocks, ONCT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Oncternal Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Oncternal Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Oncternal Therapeutics, Inc. stock shows the sell signal. See more of Oncternal Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.